Our Technology: pioneer and expert to manufacture a unique and a potent stem cell drug
Highest quality stem cells using our in-house developed and validated GMP manufacturing process and quality control to generate a defined and unique stem cell in accordance with the AMG (German Medicinal Products Act) to produce an ATMP (Advanced Therapy Medicinal Product).
TICEBA has exclusive license to the full patent portfolio on the ABCB5 gene and protein family from Boston Children's Hospital, a teaching affiliate of Harvard Medical School, Boston, Massachusetts (37+ exclusive patents).
Our groundbreaking ABCB5 researches have received widespread coverage in peer-reviewed academic journals, leading to high-end developed Potency Assays to translate research into clinical efficacy.
Off the shelf & ready to use: covering the full spectrum of clinical development from CMC to the market
High throughput stem cell production with worldwide patented technology and proprietary know-how serving market needs - anytime and anywhere.
Established and Approved Technology with high Potential: Ready for Next Generation Cell Therapeutics
Using our established and patented technology platform to feed the next generation technologies (CRISPR/Cas, iPS Technology, 3D Bioprinting...) to develop next generation of Cell Therapeutics.
a Agency Regulated tissue removal centers
b Patented technology: 37 patents exclusive with Harvard University
c Ballikaya et al., Stem Cell Res Ther. 2020 / Kerstan et a., Cytotherapy. 2021
d Isolation of ABCB5-positive Mesenchymal Stem Cells